Ghrelin News and Research

RSS

Ghrelin is a hormone produced mainly by P/D1 cells lining the fundus of the human stomach and epsilon cells of the pancreas that stimulates appetite. Ghrelin levels increase before meals and decrease after meals. It is considered the counterpart of the hormone leptin, produced by adipose tissue, which induces satiation when present at higher levels. Ghrelin is also produced in the hypothalamic arcuate nucleus where it stimulates the secretion of growth hormone from the anterior pituitary gland.

10th Annual Spring Meeting of ESC on Cardiovascular Nursing and Allied Professionals

Geneva, situated at the heart of Europe, provides a fitting setting for the 10th Annual Spring Meeting of the European Society of Cardiology Council (ESC) on Cardiovascular Nursing and Allied Professionals (CCNAP), 12 - 13 March 2010, with its special theme: "Uniting to Improve Cardiovascular Practice".

11 Feb 2010

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Tranzyme Pharma today announced that the United States Adopted Name Council (USAN) has approved the generic name “ulimorelin” for Tranzyme’s novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care (hospital-based) settings.

27 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Hunger hormone can intensify high-fat food consumption

The premise that hunger makes food look more appealing is a widely held belief - just ask those who cruise grocery store aisles on an empty stomach, only to go home with a full basket and an empty wallet.

28 Dec 2009

Hormone ghrelin influences the consumption of alcohol, study shows

A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.

23 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.

8 Dec 2009

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Study reveals that ghrelin can increase resistance to Parkinson's disease

Ghrelin, a hormone produced in the stomach, may be used to boost resistance to, or slow, the development of Parkinson's disease, Yale School of Medicine researchers report in a study published in a recent issue of the Journal of Neuroscience.

25 Nov 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

11 Nov 2009

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

19 Oct 2009

Stomach hormone ghrelin may lead to new treatments for alcohol dependence

Researchers at the Sahlgrenska Academy, Gothenburg, have discovered a new brain mechanism involved in alcohol addiction involving the stomach hormone ghrelin. When ghrelin’s actions in the brain are blocked, alcohol’s effects on the reward system are reduced. It is an important discovery that could lead to new therapies for addictions such as alcohol dependence.

30 Jun 2009

Appetite-stimulating hormone may protect muscle from atrophy

Researchers have found a potential new treatment for the common problem of muscle atrophy. Results of the animal study were presented at The Endocrine Society's 91st Annual Meeting in Washington, D.C.

13 Jun 2009

Exercise suppresses appetite by affecting appetite hormones

A vigorous 60-minute workout on a treadmill affects the release of two key appetite hormones, ghrelin and peptide YY, while 90 minutes of weight lifting affects the level of only ghrelin, according to a new study.

12 Dec 2008

Investigational drug, MK-677 shows promise for reducing age-related frailty

Researchers at the University of Virginia Health System report that a daily single oral dose of an investigational drug, MK-677, increased muscle mass in the arms and legs of healthy older adults without serious side effects, suggesting that it may prove safe and effective in reducing age-related frailty.

5 Nov 2008

Anti-frailty pill for seniors in the pipeline

An 'anti-frailty' pill for seniors could be in the pipeline - the pill which increases muscle mass in arms and legs of older adults is the brainchild of researchers at the University of Virginia Health System.

5 Nov 2008

Scientists discover a catalytic antibody that degrades a known appetite stimulant

The antibody works against the gastric hormone ghrelin (pronounced "grell-in"), which has been linked to weight gain and fat storage through its metabolic actions. These findings point towards a potentially novel treatment for obesity that would interfere directly with the some of the biological mechanisms determining weight.

28 Oct 2008

People with severe obstructive sleep apnea often have poor diets

A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.

15 Oct 2008

Helicobacter pylori may help prevent adenocarcinoma, esophageal cancers

Some bacteria may help protect against the development of a type of esophageal cancer, known as adenocarcinoma, according to a new review of the medical literature. These bacteria, which are called Helicobacter pylori, live in the stomachs of humans.

6 Oct 2008